The U.S. immunohematology market is projected to grow from USD 900 million in 2025 to around USD 1.26 billion by 2035, at a CAGR of 3.40%. Growth is driven by rising blood transfusion procedures, increasing demand for blood screening, and advancements in immunohematology diagnostic technologies.

U.S. Immunohematology Market Statical Scope

Increasing cases of chronic illnesses, emergency care admissions, and organ transplant procedures are contributing to higher testing volumes. Demand for blood typing, antibody screening, and compatibility testing is rising across hospitals and transfusion centres.

U.S. Immunohematology Market Share, By Product, 2025 (%)

• Analyzers - Analyzers lead the segment, with a share of 38%, supported by widespread adoption of laboratory automation and advanced transfusion testing systems to enhance efficiency and accuracy in blood testing workflows and reduce testing time.
• Reagents - Reagents follow, with a share of 62%, driven by continuous demand for blood typing, cross-matching, and antibody identification procedures, which require reagents due to their continuous and high-volume usage in routine testing. Expanding surgical procedures and emergency care units are contributing to higher reagent usage across hospitals and blood banks.

U.S. Immunohematology Market Share, By Technology, 2025 (%)

• Gel Cards - Gel Cards follow, with a share of 22%, supported by their reliable test interpretation and compatibility with automated laboratory systems. Hospitals and blood banks prefer gel cards for routine immunohematology testing procedures.
• Erythrocyte-Magnetized Technology - Erythrocyte-Magnetized Technology follows, with a share of 14%, driven by increasing demand for accurate and efficient blood compatibility testing. Healthcare laboratories are adopting advanced testing to improve efficiency in laboratory workflows.
• Biochips - Biochips lead the segment, with a share of 36%, driven by increasing adoption of advanced, high-precision molecular diagnostic and multiplex testing capabilities technologies in specialized laboratories. Biochip adoption improves transfusion testing precision and supports advanced research activities in immunohematology.

U.S. Immunohematology Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals lead the segment, with a share of 48%, driven by rising inpatient admissions, surgical procedures, and trauma care cases. Healthcare facilities are investing in
  advanced transfusion testing systems to improve laboratory efficiency and support growing demand for safe blood management practices.
• Diagnostic Laboratories - Diagnostic Laboratories follow, with a share of 32%, supported by rising demand for centralized testing services and automated diagnostic workflows. Laboratories are increasingly adopting advanced immunohematology technologies to improve testing accuracy and manage increasing sample volumes efficiently.

Top Companies in the U.S. Immunohematology Market

• Grifols S.A.
• Immucor Inc.
• Thermo Fisher Scientific
• Merck KGaA
• Abbott Laboratories

Segments Covered in the Report

By Product

• Analyzers
• Reagents

By Technology

• Biochips
• Gel Cards
• Microplates
• PCR
• Erythrocyte-Magnetized Technology

By End-User

• Hospitals
• Diagnostic Laboratories
• Blood banks